Table 1.
Patient characteristics
| Patient characteristics | N = 37 |
|---|---|
| Sex, n (%) | |
| F | 20 (54%) |
| M | 18 (46%) |
| Age distribution, n (%) | |
| 12 to 17 years | 6 (16%) |
| ≥18 years | 31 (84%) |
| ETI exposure in months (mean, median) | 10.7, 9.8 |
| ETI start date (mean, median) | 2/12/20, 3/12/20 |
| Age at start of ETI, median and range | 30 (12–72) |
| Insurance status, n (%) | |
| Commercial | 25 (68%) |
| Medicare | 9 (24%) |
| Medicaid | 2 (5%) |
| Affordable Care Act | 1 (3%) |
| ppFEV1 prior to starting ETI, mean, rangea | 62% (21%–117%) |
| Number with severe lung disease, n (%)b | 16 (43%) |
an = 36 (1 patient unable to perform accurate and reproducible spirometry).
bSevere lung disease defined as ppFEV1 < 40% at any time during the study period.
F = female; M = male; ETI = elexacaftor/tezacaftor/ivacaftor; ppFEV1 = percent predicted forced expiratory volume in 1 second.